Functional Neuromodulation Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Functional Neuromodulation Ltd.
NANS 2020: Boston Scientific Expects Neuromodulation Business Rebound In 2020
At NANS, Boston Scientific presented results of the COMBO study, announced a partnership with IBM Research on digital health, and reported strong US growth in its deep brain stimulation business. Boston's C suite sees rebound for lagging neuromodulation business in 2020.
Guidance Offers IDE Tips For Devices Targeting Brain Disease Progression
FDA issued a draft guidance to help device-makers conduct clinical trials for products designed to slow the progress of neurological conditions. One challenge highlighted by the agency is that changes to biomarkers measured in a study may not line up easily with disease progression.
US Neurostimulation Devices Market Forecast to Grow By $1B+ With New Indications, New Technologies
The US neurostimulation technology market will grow nearly 46% over the next five years, according to a new report from Medtech Insight.
Top Device Research Payments: PARTNER II, Cardio, Neuro, Dx Device Trials Highest In 2014
The transcatheter aortic valve PARTNER II study, several stent trials, and studies looking at diagnostic tools and neurological devices dominated the top ten trials by total payment to clinical investigators in 2014, according to an analysis of CMS' Open Payments database.
- Implantable Devices
- Surgical Equipment & Devices
Drug Discovery Tools
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.